Psychoactive Drug Market: Global Industry Analysis and Forecast (2022-2027) by Type, Application, End-User, and Region

Psychoactive Drug Market size was valued at US$ 3.7 Bn. in 2021 and the total Psychoactive Drug revenue is expected to grow at 15.2% through 2022 to 2027, reaching nearly US$ 8.65 Bn.

Psychoactive Drug Market Overview:

A psychoactive drug, also known as a psychoactive substance, or neuropsychiatric medication, is a chemical compound that alters the function of the nervous system, resulting in changes in perspective, emotion, awareness, reasoning, or behavior. These chemicals can be used for therapeutic reasons, leisure purposes, to boost efficiency or modify cognition, as psychedelics for ceremonial, mystical purposes, or study. Doctors and other healthcare providers recommend some types of psychoactive medications that have clinical benefits. Global Psychoactive Drug Market To know about the Research Methodology :- Request Free Sample Report Psychoactive chemicals frequently cause perceived (albeit objectively seen) alterations in cognition and demeanor that the individual may feel gratifying and pleasurable (exhilaration or a sensation of calm) or beneficial in a directly observable or measured way. Medications that are gratifying and hence possess positive reinforcement properties can develop addictive behavior even in the wake of negative consequences. In this report, the Psychoactive Drug market's growth reasons, as well as the market's many segments (Type, Application, End-User, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Psychoactive Drug market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Psychoactive Drug market situation.

Psychoactive Drug Market Dynamics:

The multipurpose nature of psychoactive substances is the primary driver of the psychoactive drug market. Humans utilize psychoactive chemicals for a variety of objectives to attain a certain goal. These applications differ greatly between civilizations. Some chemicals may be used for regulated or illicit reasons, while others may be used for ceremonial objectives, and yet others may be used for healing properties. Alcohol dependence, serotonergic drugs, and sleeping tablets are some examples. Caffeine is the most extensively used psychoactive stimulant in the world, yet unlike others, it is permitted and uncontrolled in almost all governments. The risks related to general anesthesia are one of the major restraints of the market. The use of antihypertensive medications, particularly general anesthetic medicines, in pediatric patients necessitates extra caution. Infants and toddlers react in different ways to anesthetic medicines than adults owing to a variety of characteristics such as bone density, enzyme production, skin temperature, pulse rate distribution, and structural development of the kidney and liver. The COVID-19 outbreak has had a substantial impact on the market for Psychoactive Drugs. The general anesthetic medicines business is facing production and supply chain problems, such as timely delivery of products to end customers and dealing with fluctuating product demand. The psychoactive drug industry is seeing short-term slower growth. It can be ascribed to causes. e.g. a reduction in sales volume from key consumers, restricted procedures in most clinics, interrupted distribution network, and difficulties in offering valuable services as a result of shutdowns.

Psychoactive Drug Market Segment Analysis:

By Type, the Cannabis segment is expected to grow at a CAGR of 9.3% in the previously mentioned forecast period. Cannabis legalization is frequently seen with mixed feelings, as it is received with mistrust due to the possibility of exploitation. Cannabis legalization has helped individuals to practice safe drug use while also discovering its medical advantages. As a result, numerous governments throughout the world are increasingly legalizing cannabis use. While most nations throughout the world have yet to legalize recreational marijuana use, attitudes about consumption and sales have shifted over time. This has resulted in an increase in the prominence of cannabis use in many countries, fueling the growth in the global cannabis segment of the psychoactive drug market. Global Psychoactive Drug Market Medical cannabis makes for a sizable portion of the psychoactive drug industry. Many nations, including Australia, Chile, Germany, Israel, the Netherlands, Poland, Portugal, and Uruguay, have allowed the medical use of cannabis. Consumers in cannabis-legalized states in the United States are primarily above the age of 45. These demographic characteristics are predicted to promote cannabis demand in the country due to the increased likelihood of chronic illnesses after the age of 45 and the efficacy of cannabis on such disorders.

Psychoactive Drug Market Regional Insights:

The market for psychoactive pharmaceuticals is dominated by the North American continent. Increased knowledge of psychological illnesses e.g. depression and anxiety in North America is predicted to drive the advancement of the psychoactive drug industry. Financial hardship, the division of family-oriented structural supports, and worsening ecological factors are also expected to drive market growth over the projection period. In 2020, 63 million people were estimated to have used opioids i.e., opiates and pharmaceutical and synthetic opioids for non-medical reasons at the global level. This corresponds to nearly 1.3% of the global population aged 14–65. The places with the highest past-year prevalence of use of opioids were North America (3.7%) and the Middle East along with South-West Asia (3.3%) and Oceania (2.7%, especially Australia and New Zealand). In Asia, although the prevalence of last year’s opioid use is at a comparable level to the global average, more than half (55%) of the estimated global number of opioid users lie in that part of the world. Despite the lack of worldwide data, the non-medical use of prescription opioids is described as a serious issue in several countries, including West and North Africa, the Near and Middle East (primarily tramadol), and North America (hydrocodone, codeine, tramadol, and fentanyl). In Western and Central Europe, there are also indicators of increased non-medical use of prescription opioids, as evidenced by an increase in the percentage of referrals to therapy for this use. The objective of the report is to present a comprehensive analysis of the Psychoactive Drug market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Psychoactive Drug market dynamics, structure by analyzing the market segments and projecting the Psychoactive Drug market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Psychoactive Drug market make the report investor’s guide.

Psychoactive Drug Market Scope: Inquire before buying

Global Psychoactive Drug Market
Report Coverage Details
Base Year: 2020 Forecast Period: 2021-2027
Historical Data: 2016 to 2020 Market Size in 2020: US $ 3.7 Bn.
Forecast Period 2021 to 2027 CAGR: 15.2% Market Size in 2027: US $ 8.65 Bn.
Segments Covered: by Type • Diphenhydramine (Benadryl) • Amanita muscaria mushroom • Tylenol 3 (contains codeine) • Codeine • Pipe tobacco • Bupropion (Zyban) • Cannabis • Hashish • Other
by Application • Anesthesia • Pain management • Mental disorders • Recreation • Ritual and spiritual • Military • Other
by End-User • Hospitals • Homecare • Specialty Clinics • Other

Psychoactive Drug Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Psychoactive Drug Market Key Players

Abbott Laboratories • Sanofi S.A. • Cipla Limited • Biocon Limited • Intas Pharmaceuticals Ltd. • Sun Pharmaceutical Industries Ltd. • Cadila Pharmaceuticals • Lupin Limited • Emcure Pharmaceuticals Ltd. • Novartis International AG • Dr. Reddy’s Laboratories Limited • Alkem Laboratories Limited • The Emmes Company • Klarisana • AstraZeneca • F. Hoffmann-La Roche Ltd FAQs: 1. Which is the potential market for the Psychoactive Drug in terms of the region? Ans. The market for psychoactive pharmaceuticals is dominated by the North American continent 2. What are the opportunities for new market entrants? Ans. The multipurpose nature of psychoactive substances is the primary driver of the psychoactive drug market. 3. What is expected to drive the growth of the Psychoactive Drug market in the forecast period? Ans. The multipurpose nature of psychoactive substances is the primary driver of the psychoactive drug market. 4. What is the projected market size & growth rate of the Psychoactive Drug Market? Ans. Psychoactive Drug Market size was valued at US$ 3.7 Bn. in 2021 and the total Psychoactive Drug revenue is expected to grow at 15.2% through 2022 to 2027, reaching nearly US$ 8.65 Bn. 5. What segments are covered in the Psychoactive Drug Market report? Ans. The segments covered are Type, Application, End-User, and Region.
1. Global Psychoactive Drug Market: Research Methodology 2. Global Psychoactive Drug Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Psychoactive Drug Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Psychoactive Drug Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Psychoactive Drug Market Segmentation 4.1 Global Psychoactive Drug Market, by Type (2022-2027) • Diphenhydramine (Benadryl) • Amanita muscaria mushroom • Tylenol 3 (contains codeine) • Codeine • Pipe tobacco • Bupropion (Zyban) • Cannabis • Hashish • Other 4.2 Global Psychoactive Drug Market, by Application (2022-2027) • Anesthesia • Pain management • Mental disorders • Recreation • Ritual and spiritual • Military • Other 4.3 Global Psychoactive Drug Market, by End-User (2022-2027) • Hospitals • Homecare • Specialty Clinics • Other 5. North America Psychoactive Drug Market(2022-2027) 5.1 Global Psychoactive Drug Market, by Type (2022-2027) • Diphenhydramine (Benadryl) • Amanita muscaria mushroom • Tylenol 3 (contains codeine) • Codeine • Pipe tobacco • Bupropion (Zyban) • Cannabis • Hashish • Other 5.2 Global Psychoactive Drug Market, by Application (2022-2027) • Anesthesia • Pain management • Mental disorders • Recreation • Ritual and spiritual • Military • Other 5.3 Global Psychoactive Drug Market, by End-User (2022-2027) • Hospitals • Homecare • Specialty Clinics • Other 5.4 North America Psychoactive Drug Market, by Country (2022-2027) • United States • Canada • Mexico 6. Asia Pacific Psychoactive Drug Market (2022-2027) 6.1. Asia Pacific Psychoactive Drug Market, by Type (2022-2027) 6.2. Asia Pacific Psychoactive Drug Market, by Application (2022-2027) 6.2. Asia Pacific Psychoactive Drug Market, by End-User (2022-2027) 6.2. Asia Pacific Psychoactive Drug Market, by Country (2022-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Psychoactive Drug Market (2022-2027) 7.1 Middle East and Africa Psychoactive Drug Market, by Type (2022-2027) 7.2. Middle East and Africa Psychoactive Drug Market, by Application (2022-2027) 7.2. Middle East and Africa Psychoactive Drug Market, by End-User (2022-2027) 7.4. Middle East and Africa Psychoactive Drug Market, by Country (2022-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Psychoactive Drug Market (2022-2027) 8.1. Latin America Psychoactive Drug Market, by Type (2022-2027) 8.2. Latin America Psychoactive Drug Market, by Application (2022-2027) 8.2. Latin America Psychoactive Drug Market, by End-User (2022-2027) 8.4 Latin America Psychoactive Drug Market, by Country (2022-2027) • Brazil • Argentina • Rest Of Latin America 9. European Psychoactive Drug Market (2022-2027) 9.1. European Psychoactive Drug Market, by Type (2022-2027) 9.2. European Psychoactive Drug Market, by Application (2022-2027) 9.3. European Psychoactive Drug Market, by End-User (2022-2027) 9.4. European Psychoactive Drug Market, by Country (2022-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1 Abbott Laboratories 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Sanofi S.A. 10.3 Cipla Limited 10.4 Biocon Limited 10.5 Intas Pharmaceuticals Ltd. 10.6 Sun Pharmaceutical Industries Ltd. 10.7 Cadila Pharmaceuticals 10.8 Lupin Limited 10.9 Emcure Pharmaceuticals Ltd. 10.10 Novartis International AG 10.11 Dr. Reddy’s Laboratories Limited 10.12 Alkem Laboratories Limited 10.13 The Emmes Company 10.14 Klarisana 10.15 AstraZeneca 10.16 F. Hoffmann-La Roche Ltd

About This Report

Report ID 36268
Category Medical Devices
Published Date Nov 2019
Updated Date Feb 2022
Contact Us